[go: up one dir, main page]

SI2018153T1 - Tekoči oralni sestavki - Google Patents

Tekoči oralni sestavki

Info

Publication number
SI2018153T1
SI2018153T1 SI200730938T SI200730938T SI2018153T1 SI 2018153 T1 SI2018153 T1 SI 2018153T1 SI 200730938 T SI200730938 T SI 200730938T SI 200730938 T SI200730938 T SI 200730938T SI 2018153 T1 SI2018153 T1 SI 2018153T1
Authority
SI
Slovenia
Prior art keywords
aqueous suspension
simvastatin
agent
oral compositions
liquid oral
Prior art date
Application number
SI200730938T
Other languages
English (en)
Inventor
Phillip Driver
Original Assignee
Rosemont Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosemont Pharmaceuticals Ltd filed Critical Rosemont Pharmaceuticals Ltd
Publication of SI2018153T1 publication Critical patent/SI2018153T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A63—SPORTS; GAMES; AMUSEMENTS
    • A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
    • A63B21/00—Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices
    • A63B21/02—Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices using resilient force-resisters
    • A—HUMAN NECESSITIES
    • A63—SPORTS; GAMES; AMUSEMENTS
    • A63B—APPARATUS FOR PHYSICAL TRAINING, GYMNASTICS, SWIMMING, CLIMBING, OR FENCING; BALL GAMES; TRAINING EQUIPMENT
    • A63B2225/00—Miscellaneous features of sport apparatus, devices or equipment
    • A63B2225/09—Adjustable dimensions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Education & Sports Medicine (AREA)
SI200730938T 2006-04-26 2007-04-26 Tekoči oralni sestavki SI2018153T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US74565306P 2006-04-26 2006-04-26
PCT/GB2007/001552 WO2007125339A1 (en) 2006-04-26 2007-04-26 Liquid oral compositions
EP07732588A EP2018153B1 (en) 2006-04-26 2007-04-26 Liquid oral compositions

Publications (1)

Publication Number Publication Date
SI2018153T1 true SI2018153T1 (sl) 2012-08-31

Family

ID=38520565

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200730938T SI2018153T1 (sl) 2006-04-26 2007-04-26 Tekoči oralni sestavki

Country Status (13)

Country Link
US (2) US9597289B2 (sl)
EP (1) EP2018153B1 (sl)
JP (1) JP2009534459A (sl)
CN (1) CN101431982A (sl)
AT (1) ATE552825T1 (sl)
AU (1) AU2007245410A1 (sl)
CY (1) CY1112917T1 (sl)
DK (1) DK2018153T3 (sl)
ES (1) ES2385752T3 (sl)
PL (1) PL2018153T3 (sl)
PT (1) PT2018153E (sl)
SI (1) SI2018153T1 (sl)
WO (1) WO2007125339A1 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2018153E (pt) * 2006-04-26 2012-07-04 Rosemont Pharmaceuticals Ltd Composições orais líquidas
GB2497728A (en) * 2011-12-14 2013-06-26 Londonpharma Ltd Statin formulations for transmucosal delivery
CN104586761A (zh) * 2013-10-30 2015-05-06 上海信谊药厂有限公司 辛伐他汀纳米混悬剂及其制备方法
JP6832195B2 (ja) * 2016-03-03 2021-02-24 ライオン株式会社 経口液剤及び経口固形剤
WO2017212409A1 (en) 2016-06-08 2017-12-14 Ftf Pharma Private Limited A novel pharmaceutical composition of a lipid lowering compound
GB201704687D0 (en) 2017-03-24 2017-05-10 Wockhardt Uk Ltd Pharmaceutical composition of simvastatin or salt thereof
CN108403630A (zh) * 2018-05-31 2018-08-17 佛山市南海东方澳龙制药有限公司 混悬剂及其制备方法
CN110812326B (zh) * 2019-11-04 2022-04-22 黑龙江省农业科学院畜牧兽医分院 一种辛伐他汀混悬乳剂及其制备方法和应用

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) * 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
US5112604A (en) * 1989-09-01 1992-05-12 Riker Laboratories, Inc. Oral suspension formulation
US5948438A (en) * 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
IL123902A (en) * 1995-11-02 2003-01-12 Warner Lambert Co PHARMACEUTICAL COMPOSITION FOR REGULATING LIPID CONCENTRATION CONTAINING ACYL-CoA CHOLESTEROL O-ACYLTRANSFERASE (ACAT) INHIBITOR AND AN HMG-CoA REDUCTASE INHIBITOR
DE19541260A1 (de) * 1995-11-06 1997-05-07 Lohmann Therapie Syst Lts Therapeutische Zubereitung zur transdermalen Applikation von Wirkstoffen durch die Haut
US20050038102A1 (en) 1997-10-14 2005-02-17 Brigham And Womens Hospital Upregulation of type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors
EP0940395A1 (en) * 1998-03-05 1999-09-08 Synthon B.V. Process for producing simvastatin and/or its derivatives
US6184220B1 (en) * 1998-03-27 2001-02-06 Boehringer Ingelheim Pharma Kg Oral suspension of pharmaceutical substance
CA2240983A1 (en) * 1998-06-18 1999-12-18 Yong Tao Process to manufacture simvastatin and intermediates
US20010006656A1 (en) 1999-02-17 2001-07-05 University Of Washington Methods and compositions for inhibiting inflammation associated with pulmonary disease
US6696086B1 (en) * 1999-09-10 2004-02-24 Lek Pharmaceuticals D.D. Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparation
WO2001034590A1 (en) * 1999-11-11 2001-05-17 Biocon India Limited Process for manufacturing simvastatin and the novel intermediates
FR2801508B1 (fr) 1999-11-29 2003-11-14 Oreal Utilisation d'inhibiteurs d'hmg coa-reductase pour le traitement de la seborrhee
US6534537B2 (en) * 2000-01-07 2003-03-18 Kenneth Weisman Use of HMG-COA reductase inhibitors to prevent and treat BPH
CN1215064C (zh) * 2000-03-30 2005-08-17 第一制糖株式会社 辛伐他汀的制备方法
US6806290B2 (en) * 2000-06-09 2004-10-19 Lek Pharmaceuticals D.D. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
RU2275909C2 (ru) * 2000-07-27 2006-05-10 Плас Кемиклс Б.В. Способы получения симвастатина высокой степени очистки и полусинтетических статинов
DE10057648A1 (de) 2000-11-21 2002-06-06 Univ Jw Goethe Frankfurt Main Verwendung von Inhibitoren von 3-Hydroxyl-3-methylglutaryl-Coenzym-A-Reduktase
AU2002221131A1 (en) 2000-12-14 2002-06-24 Sankyo Company Limited Blood lipid ameliorant composition
PT1363516E (pt) * 2001-02-27 2005-11-30 Chong Kun Dang Pharm Corp Um processo melhorado para a preparacao da sinvastatina
EP1372662A1 (en) * 2001-03-05 2004-01-02 Ortho-Mcneil Pharmaceutical, Inc. Taste masked liquid pharmaceutical compositions
FR2821745B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Granules et granules enrobes au gout masque
WO2002094803A1 (en) * 2001-05-18 2002-11-28 Aurobindo Pharma Limited A process for lactonization to produce highly pure simvastatin
US6797831B2 (en) * 2001-05-18 2004-09-28 Aurobindo Pharma Limited Process for lactonization to produce simvastatin
CA2450238A1 (en) 2001-06-12 2002-12-19 Galephar M/F Oral pharmaceutical composition containing a statin derivative
FR2827770B1 (fr) 2001-07-27 2005-08-19 Gattefosse Ets Sa Composition pharmaceutique a usage oral comprenant un principe actif susceptible de subir un important effet de premier passage intestinal
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
US20030065019A1 (en) 2001-09-19 2003-04-03 Francois Mach Treatment of rheumatoid arthritis with statins (HMG-CoA reductase inhibitors)
US6709600B2 (en) 2001-09-21 2004-03-23 The Regents Of The University Of California Method for removing organic liquids from aqueous solutions and mixtures
US20040142902A1 (en) 2001-11-08 2004-07-22 Struijker- Boudier Harry A.J. Implant dosage form and use thereof for the delivery of a cholosterol lowering agent
US20040018248A1 (en) 2001-11-29 2004-01-29 Adrianne Bendich Composition containing statins and calcium for improved cardiovascular health
US7101572B2 (en) * 2001-12-07 2006-09-05 Unilab Pharmatech, Ltd. Taste masked aqueous liquid pharmaceutical composition
CN1620282A (zh) * 2001-12-20 2005-05-25 法马西亚公司 用于口服给药的药物混悬液
US20030162827A1 (en) 2002-01-30 2003-08-28 Suresh Venkataram HMG CoA reductase inhibiting composition, method of preparation thereof and method for competitively inhibiting HMG CoA reductase using such composition
ES2192988B1 (es) 2002-02-28 2005-02-16 Jose Manuel Quesada Gomez Nuevas aplicaciones de las estatinas en dermatologia y las correspondientes formulaciones farmaceuticas.
US7074825B2 (en) 2002-03-07 2006-07-11 Huanbiao Mo Composition and method for treating cancer
US6603022B1 (en) * 2002-05-10 2003-08-05 Biocon India Limited Process for manufacturing Simvastatin and novel intermediates thereof
AU2003245313A1 (en) 2002-06-10 2003-12-22 Elan Pharma International, Ltd Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives (statins), novel combinations thereof as well as manufacturing of these pharmaceutical compositions
US20050182106A1 (en) 2002-07-11 2005-08-18 Sankyo Company, Limited Medicinal composition for mitigating blood lipid or lowering blood homocysteine
WO2004006919A1 (ja) * 2002-07-11 2004-01-22 Sankyo Company, Limited 血中脂質改善又は血中ホモシステイン低下のための医薬組成物
US20050182036A1 (en) 2002-08-02 2005-08-18 Sankyo Company, Limited Medicinal composition containing an HMG-CoA reductase inhibitor
US20050187204A1 (en) 2002-08-08 2005-08-25 Sankyo Company, Limited Medicinal composition for lowering blood lipid level
EP1545503A4 (en) 2002-09-03 2007-12-12 Circ Pharma Res And Dev Ltd PHARMACEUTICAL FORMULATIONS AND METHODS FOR MODIFIED RELEASE OF STATINES
AU2003270487A1 (en) 2002-09-11 2004-04-30 The Board Of Trustees Of The University Of Arkansas Use of statins in the prevention and treatment of radiation injury and other disorders associated with reduced endothelial thrombomodulin
CN100486572C (zh) * 2002-11-04 2009-05-13 饶品昌 他汀类药物新剂型
KR20050098313A (ko) * 2003-02-11 2005-10-11 플러스 케미칼스 비.브이. 제어된 범위의 심바스타틴 이량체 함량을 갖는심바스타틴의 제조 방법
US20050119330A1 (en) 2003-03-17 2005-06-02 Kao Peter N. Use of antiproliferative agents in the treatment and prevention of pulmonary proliferative vascular diseases
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
WO2005044258A1 (en) 2003-11-05 2005-05-19 Teva Pharmaceutical Industries Ltd. Simvastatin formulations and methods of making same
EP1722780A4 (en) 2003-11-26 2008-12-17 Univ Duke METHOD FOR PREVENTING OR TREATING GLAUCOMA
EP1563837A1 (en) 2004-02-03 2005-08-17 Ferrer Internacional, S.A. Hypocholesterolemic compositions comprising a statin and an antiflatulent agent
DE602005008935D1 (de) 2004-04-26 2008-09-25 Alcon Inc Statine zur behandlung von okularer hypertonie und glaukom
US20050267197A1 (en) 2004-05-25 2005-12-01 Roger Berlin Compositions containing policosanol and HMG-Co-A reductase inhibitor and their pharmaceutical uses
JP2006022039A (ja) * 2004-07-08 2006-01-26 Towa Yakuhin Kk 高い安定性を有するシンバスタチン固形製剤
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
FR2898492B1 (fr) * 2006-03-15 2008-06-06 Pierre Fabre Medicament Sa Comprimes orodispersibles de domperidone
PT2018153E (pt) * 2006-04-26 2012-07-04 Rosemont Pharmaceuticals Ltd Composições orais líquidas
CA2701695A1 (en) * 2007-10-09 2009-04-16 Novartis Ag Pharmaceutical formulation of valsartan

Also Published As

Publication number Publication date
US10300041B2 (en) 2019-05-28
CN101431982A (zh) 2009-05-13
EP2018153B1 (en) 2012-04-11
CY1112917T1 (el) 2016-04-13
ES2385752T3 (es) 2012-07-31
AU2007245410A1 (en) 2007-11-08
ATE552825T1 (de) 2012-04-15
US20090311330A1 (en) 2009-12-17
PT2018153E (pt) 2012-07-04
JP2009534459A (ja) 2009-09-24
DK2018153T3 (da) 2012-07-23
WO2007125339A1 (en) 2007-11-08
US9597289B2 (en) 2017-03-21
PL2018153T3 (pl) 2012-09-28
EP2018153A1 (en) 2009-01-28
US20170143669A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
CY1112917T1 (el) Υγρες στοματικες συνθεσεις
NZ595526A (en) Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
MX2010003923A (es) Formulacion farmaceutica de valsartan.
WO2007041156A3 (en) Antibiotic formulations, unit doses, kits, and methods
TW200744677A (en) Compositions and methods for preparation of poorly water soluble drugs with increased stability
TW200600118A (en) Pharmaceutical suspension composition
EP2671584A3 (en) Compositions and methods for treating disorders associated with salt or fluid retention
MA33044B1 (fr) Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
UA105078C2 (uk) Фармацевтична композиція, яка містить тетрагідрофолієву кислоту
MA30725B1 (fr) Administration d'inhibiteurs de la dipeptidyl peptidase
JP2009531457A5 (sl)
ES2720954T3 (es) Formulaciones estabilizadas de estatina
MX2010005198A (es) Composiciones liquidas que comprenden valsartan.
TW200716202A (en) Pediatric formulation of topiramate
RU2012113844A (ru) Пероральные суспензионные лекарственные формы ацетата эсликарбазепина
GEP20135805B (en) 1-(ARYLSULFONYL)-4-(PIPERAZIN-1-YL)-1H-BENZIMIDAZOLES AS δ-HYDROXYTRYPTAMINE-6 LIGANDS
UA102376C2 (ru) Стойкая жидкая фармацевтическая композиция на основе тразодона
MX2010006896A (es) Ingrediente farmaceutico activo en un soporte solido, amorfo y con una solubilidad mejorada.
IL186058A0 (en) Polymorphs of 3-0-(3',3' -dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine salt
FI3554474T3 (fi) Mikafungiinikoostumuksia
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
MX2017015202A (es) Formulaciones liquidas de celecoxib para administracion oral.
ZA202203563B (en) Pediatric suspension formulation
MY139455A (en) Pharmaceutical composition comprising 5-methyl-2-2'(chloro-6'-fluoroanilino) phenylacetic acid
CY1120050T1 (el) Φαρμακοτεχνικες μορφες για την αποδεσμευση δραστικων ενωσεων